Cellectis SA (CLLS) Earnings Date & Reports

Cellectis SA is aÂ clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

CLLS is expected to report earnings to rise 50.06% to -24 cents per share on May 07

Cellectis SA CLLS Stock Earnings Reports

Q1'25

Est.

$-0.24

Q4'24

Missed

by $0.07

Q3'24

Missed

by $0.03

Q2'24

Beat

by $0.01

Q1'24

Beat

by $0.41

The last earnings report on March 14 showed earnings per share of -15 cents, missing the estimate of -9 cents. With 126.73K shares outstanding, the current market capitalization sits at 164.83M.

View a ticker or compare two or three

Compare

CLLS